This depletion effect is consistent with prior clinical observations in DLBCL (rapid reduction post-first dose maintained for ≥24 weeks) (12, 18) and idiopathic thrombocytopenic purpura (0% CD19+ within one week of treatment) (19). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.